PharmaCyte Biotech Announces Update on Corporate Changes
January 08 2015 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live cell encapsulation
technology, Cell-in-a-Box®, today announced that the Company is
trading under its new ticker symbol "PMCB" effective today. It also
announced that PharmaCyte Biotech's CUSIP number has been changed
to 71715X104.
Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte
Biotech, commented, "We have been asked by FINRA to use the ticker
symbol "PMCB" rather than the ticker symbol that we announced
yesterday. We are pleased to begin trading under our new corporate
name and ticker symbol and look forward to 2015, our first full
year operating solely as a biotechnology firm, with great
expectations."
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as Cell-in-a-Box®. This unique
and patented technology will be used as a platform upon which
treatments for several types of cancer, including advanced,
inoperable pancreatic cancer, and diabetes are being built.
PharmaCyte Biotech's treatment for pancreatic cancer involves low
doses of the well-known anticancer prodrug ifosfamide, together
with encapsulated live cells, which convert ifosfamide into its
active or "cancer-killing" form. These capsules are placed as close
to the cancerous tumor as possible to enable the delivery of the
highest levels of the cancer-killing drug at the source of the
cancer. This "targeted chemotherapy" has proven remarkably
effective in past clinical trials. PharmaCyte Biotech is also
working towards improving the quality of life for patients with
advanced pancreatic cancer and on treatments for other types of
solid cancerous tumors. In addition, PharmaCyte Biotech is
developing treatments for cancer based upon chemical constituents
of the Cannabis plant, known as cannabinoids. In doing so,
PharmaCyte Biotech is examining ways to exploit the benefits of
Cell-in-a-Box® technology in optimizing the anticancer
effectiveness of cannabinoids, while minimizing or outright
eliminating the debilitating side effects usually associated with
cancer treatments. This provides PharmaCyte Biotech the rare
opportunity to develop "green" approaches to fighting deadly
diseases, such as cancer of the pancreas, brain and breast, which
affect hundreds of thousands of individuals worldwide every
year.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte Biotech or its
management, are intended to identify forward-looking statements.
Important factors, many of which are beyond the control of
PharmaCyte Biotech, could cause actual results to differ materially
from those set forth in the forward-looking statements. They
include PharmaCyte's ability to continue as a going concern, delays
or unsuccessful results in clinical trials or flaws or defects
regarding its product candidates, changes in relevant legislation
or regulatory requirements, uncertainty of protection of PharmaCyte
Biotech's intellectual property and PharmaCyte Biotech's continued
ability to raise capital. PharmaCyte Biotech does not assume
any obligation to update any of these forward-looking
statements.
More information about PharmaCyte Biotech can be found at
www.PharmaCyteBiotech.com. It can also be obtained by contacting
Investor Relations.
CONTACT: Investor Relations Contacts:
Jamien Jones
Blueprint Life Science Group
Telephone: 415.375.3340 Ext. 103
jjones@bplifescience.com